A collaboration between the College of American Pathologists (CAP), the Association for Molecular Pathology (AMP), and the International Association for the Study of Lung Cancer (IASLC) has resulted in updated guidelines for molecular testing in lung cancer patients. The change in testing guidelines provides an additional opportunity to identify therapeutic targets in the ROS1 gene. While EGFR and ALK have been the standard of care as part of an initial diagnostic workup for lung cancer patients, the new guidelines recommend ROS1 testing as well. CSI Laboratories’ C•RESULTS Lung Cancer Panel includes all of the recommended genes for initial genomic testing of lung cancer patients: EGFR (including the T790M mutation), ALK, and ROS1. Additionally, CSI’s C•RESULTS Lung Cancer Panel includes PD-L1 testing to assist with immunotherapy selection as well as BRAF mutation testing.
To read more about the recommended changes, visit the College of American Pathologists’ Updated Molecular Testing Guidelines for Lung Cancer Patients.
For additional information on the C•RESULTS Lung Cancer Panel, review the panel information here, contact your local Territory Sales Specialist, or call CSI Client Service at 800-459-1185.